Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036738 | 0.99 | ERBB2 (0.43) | ERBB2CRHR1TLR8HSP90AA1HSP90AB1 | |
| SCHEMBL7032248 | 0.91 | HSP90B1 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7028964 | 0.91 | HSP90B1 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7032141 | 0.89 | HSP90B1 (0.45) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7032761 | 0.88 | TLR8 (0.42) | ERBB2TLR8HSP90AA1HSP90AB1 | |
| SCHEMBL7029124 | 0.87 | ERBB2 (0.55) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7033056 | 0.87 | ERBB2 (0.55) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7035445 | 0.86 | ERBB2 (0.40) | ERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL7029061 | 0.86 | ERBB2 (0.40) | ERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL7031052 | 0.86 | ERBB2 (0.56) | ERBB2CRHR1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642230-B2 | Administering novel compounds which bind to corticotropin releasing factor receptors, thereby altering anxiogenic effects of CRF secretion | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-06-19 | — | — | US | disclosed |
| US-6362180-B1 | ANTAGONIST TO CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-6143743-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | CRH, CRHR1, CRHR2 | ERBB2 2186/4885CRHR1 2/4885TLR8 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.